Summary of Conference Call Notes Company Overview - **Company**: 来凯医药 (LaiKai Pharmaceutical) - **Key Products**: LAE102 (ActRIIA), LAE002 (Afuresertib), LAE103 (ActRIIB), LAE123, LAE124 Industry Insights - **Market Focus**: The company is focused on the development of innovative therapies in the fields of muscle gain and fat loss, particularly through the ActRIIA and ActRIIB pathways. Key Points and Arguments LAE102 (ActRIIA) - **Clinical Data**: - In the Chinese MAD group, after 4 weeks, lean body mass increased by 4.6% and fat mass decreased by 3.6% - In the US SAD group, lean body mass increased by over 5% and fat mass decreased by over 2% - Safety profile is good with no racial differences observed [2][5][13] - **Future Plans**: - A 24-week MAD extension trial with 60 subjects has been initiated, with data expected in Q3 2026 - A phase II clinical trial in combination with GLP-1 is set to start soon [2][5][10] LAE002 (Afuresertib) - **Commercialization Timeline**: - Phase III trial completed enrollment in October 2025, with top-line data expected in Q2 2026 - NDA submission planned for late 2026, aiming for market launch in 2027 - Collaboration with Qilu Pharmaceutical for sales in Greater China, with a total agreement value of 2.045 billion RMB, including a pre-approval payment of 530 million RMB [2][12] - **Market Potential**: - Peak sales for similar drugs (e.g., AstraZeneca's Capivasertib) projected to reach 1-2 billion USD [12] Financial Performance - **2025 Financials**: - Revenue confirmed at 107 million RMB, primarily from LAD002 licensing agreement - Management and R&D expenses totaled 356 million RMB, focused on advancing ActRII pipeline - Loss narrowed from 254 million RMB in 2024 to 229 million RMB in 2025 - Cash reserves at 1.26 billion RMB, sufficient for 3-4 years of operations at a burn rate of approximately 350 million RMB per year [3][4][16] Competitive Landscape - **Differentiation**: - ActRII antibody is leading in the muscle gain and fat loss sector, outperforming preclinical small nucleic acid drugs - Unlike APOC3/AGT-targeting drugs that only reduce fat, ActRII also promotes muscle mass increase, providing a competitive edge [4][9] Pipeline Clarity - **Upcoming Milestones**: - LAE103 (ActRIIB) phase I trial initiated in Australia, with data expected in Q3 2026 - LAE123 (dual-targeting ActRIIA/B antibody) IND submission planned for 2026 - LAE124 (oral GIPR agonist) expected to complete PCC in 2026 [2][6][11] Strategic Partnerships - **BD Strategy**: - Open to collaborations with multinational pharmaceutical companies to accelerate overseas clinical development for LAE102 - Focus on partners with strong commitments and financial capabilities [13][15] R&D and Commercialization Capability - **Execution Strength**: - The company has demonstrated strong R&D capabilities and timely milestone achievements - Confidence in maintaining a leading position globally due to first-mover advantages and deep understanding of signaling pathways [16] Overall Outlook - **Future Expectations**: - Anticipation of significant milestones and catalysts in 2026 to enhance company valuation and investor returns [16]

Core Viewpoint - The announcement of a licensing agreement between Lai Kai Pharmaceutical and Qilu Pharmaceutical for the commercialization of the breast cancer candidate drug LAE002 (Afuresertib) in China has positively impacted Lai Kai's stock price, which rose by 4.24% to HKD 11.8 [1] Group 1: Licensing Agreement Details - Lai Kai Pharmaceutical has entered into an exclusive licensing agreement with Qilu Pharmaceutical for LAE002, aimed at accelerating its commercialization in China [1] - The agreement stipulates that Lai Kai is entitled to receive a non-refundable upfront payment of up to RMB 530 million and milestone payments related to clinical development until the first indication receives new drug application approval in China [1] - Additionally, Lai Kai is eligible for a total of up to RMB 2.045 billion in upfront and milestone payments, along with a tiered sales revenue share ranging from over ten percentage points to over twenty percentage points on future net sales in China [1] Group 2: Clinical Trial Progress - The Phase III clinical trial (AFFIRM-205) for LAE002 targeting HR+/HER2- breast cancer is currently progressing as planned [1]